MA32305B1 - Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine - Google Patents

Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine

Info

Publication number
MA32305B1
MA32305B1 MA33349A MA33349A MA32305B1 MA 32305 B1 MA32305 B1 MA 32305B1 MA 33349 A MA33349 A MA 33349A MA 33349 A MA33349 A MA 33349A MA 32305 B1 MA32305 B1 MA 32305B1
Authority
MA
Morocco
Prior art keywords
bluetongue
virus vaccine
live virus
attenuated live
inactivated attenuated
Prior art date
Application number
MA33349A
Other languages
Arabic (ar)
English (en)
Inventor
Baptiste Dungu
Teichmann Beate Von
Ian Louw
Original Assignee
Onderstepoort Biolog Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onderstepoort Biolog Products Ltd filed Critical Onderstepoort Biolog Products Ltd
Publication of MA32305B1 publication Critical patent/MA32305B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur la préparation d'une composition de virus inactivé de la fièvre catarrhale ovine (btv) et, en particulier, sur un vaccin utilisant une souche de vaccin vivant atténué de la btv en tant que souche-mère. Le vaccin peut être administré à un animal pour empêcher la fièvre catarrhale ovine par déclenchement d'une réponse immunitaire contre le ou les sérotypes du virus de la fièvre catarrhale ovine inclus dans la composition.
MA33349A 2008-04-16 2010-11-11 Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine MA32305B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200803366 2008-04-16
PCT/IB2009/051590 WO2009128043A1 (fr) 2008-04-16 2009-04-16 Vaccin contre le virus vivant atténué inactivé de la fièvre catarrhale ovine

Publications (1)

Publication Number Publication Date
MA32305B1 true MA32305B1 (fr) 2011-05-02

Family

ID=40786489

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33349A MA32305B1 (fr) 2008-04-16 2010-11-11 Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine

Country Status (6)

Country Link
US (1) US20110091500A1 (fr)
EP (1) EP2280729A1 (fr)
AP (1) AP3215A (fr)
MA (1) MA32305B1 (fr)
WO (1) WO2009128043A1 (fr)
ZA (1) ZA201008125B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2944322B1 (fr) * 2010-03-12 2018-01-17 Merial, Inc Vaccins de recombinaison du virus de la fièvre catarrhale et utilisations de ceux-ci
HK1216006A1 (zh) * 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
WO2014167582A2 (fr) * 2013-03-31 2014-10-16 Ella Foundation Composition de vaccin contre la prophylaxie chez des ruminants
US20170247665A1 (en) * 2014-08-29 2017-08-31 Biovet Private Limited A bluetongue vaccine and methods of manufacture thereof
CN112870346A (zh) * 2021-01-21 2021-06-01 云南省畜牧兽医科学院 一种蓝舌病病毒二价灭活疫苗的制备方法

Also Published As

Publication number Publication date
ZA201008125B (en) 2012-02-29
WO2009128043A1 (fr) 2009-10-22
AP2010005446A0 (en) 2010-12-31
AP3215A (en) 2015-04-30
US20110091500A1 (en) 2011-04-21
EP2280729A1 (fr) 2011-02-09

Similar Documents

Publication Publication Date Title
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
BRPI0923448A2 (pt) vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
MX2012002654A (es) Compuestos y composiciones como moduladores de la actividad de tlr.
MX2013004817A (es) Enfermedad inflamatoria.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
AU2011280259A8 (en) Influenza vaccine
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
CR20130054A (es) Procesos para preparar compuestos antivirales
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
CA2915027A1 (fr) Compositions et procedes d'administration de vaccins contre le virus de la dengue
MA32305B1 (fr) Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine
BR112012014624A2 (pt) suspensão homogênea de compostos de imunopotenciação e usos dos destes
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
CU20110042A7 (es) Molécula inmunogénica que comprende un ligando de invasión dirigido a un receptor resistente a proteasas
EA033027B1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.